Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPension (IS)Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Harvard Bioscience (HBIO) Long-Term Debt Issuances (2016 - 2021)

Harvard Bioscience (HBIO) has disclosed Long-Term Debt Issuances for 11 consecutive years, with $1.8 million as the latest value for Q4 2021.

  • Quarterly Long-Term Debt Issuances fell 96.62% to $1.8 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $59.4 million through Dec 2021, up 3.93% year-over-year, with the annual reading at $40.0 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Issuances for Q4 2021 was $1.8 million at Harvard Bioscience, down from $2.5 million in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $67.0 million in Q1 2018, with the low at -$100000.0 in Q4 2018.
  • Average Long-Term Debt Issuances over 5 years is $9.8 million, with a median of $1.9 million recorded in 2019.
  • Peak annual rise in Long-Term Debt Issuances hit 6600.0% in 2018, while the deepest fall reached 120.0% in 2018.
  • Over 5 years, Long-Term Debt Issuances stood at $500000.0 in 2017, then plummeted by 120.0% to -$100000.0 in 2018, then skyrocketed by 2100.0% to $2.0 million in 2019, then soared by 2485.0% to $51.7 million in 2020, then tumbled by 96.62% to $1.8 million in 2021.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at $1.8 million, $2.5 million, and $51.7 million for Q4 2021, Q3 2021, and Q4 2020 respectively.